In memoriam: Tadashi Inagami
Tadashi Inagami, an emeritus biochemistry professor at Vanderbilt University known for his pioneering research contributions to hypertension, heart failure, and vascular disease, died on March 13 in Pittsburgh. He was 92.

Born in Kobe, Japan, on Feb. 20, 1931, Inagami earned a bachelor’s degree in nutritional chemistry from Kyoto University in 1953. In 1958, he earned a Ph.D. in biophysical chemistry from Yale University through the Fulbright Foreign Student Program. He earned a second doctoral degree from Kyoto University in 1963.
In 1966, Inagami became an assistant professor in biochemistry at Vanderbilt University School of Medicine, where he developed a reputation for being helpful, generous with his time, polite, gentle, and humble. He remained at Vanderbilt until his retirement in 2014.
Inagami was the first researcher to purify mouse renin and obtain its primary structure. He identified and cloned the angiotensin II type 1 receptor and angiotensin type 2 receptor, deepening understanding of angiotensin II signal transduction and its role in cardiovascular health. He also characterized the primary structure of the rat atrial natriuretic peptide hormone, which upregulates salt excretion and lowers blood volume resulting in low blood pressure. He discovered that the angiotensin II signaling pathway leads to high cell proliferation in the heart, kidney, and blood vessel walls. These findings contributed to creation of medication to lower hypertension, such as angiotensin II type 1 receptor blockers, and treatments for heart failure and vascular and kidney disease.
For 17 years, Inagami served as director of the interdisciplinary Specialized Center of Research in Hypertension at Vanderbilt. He published more than 500 scientific articles and mentored more than 100 graduate students and postdoctoral fellows. His many accolades included the American Heart Association/American Stroke Association Distinguished Scientist Award, the CIBA Award for Hypertension Research, and the Japan Academy Prize. Vanderbilt honored him with the Earl Sutherland Prize for Achievement in Research in 1990.
After his retirement, Inagami and his wife, Masako, moved to Pittsburgh, where he loved attending his grandchildren’s baseball games and dance and violin recitals, and he enjoyed strolling through Squirrel Hill and Frick Park and exploring Japanese restaurants.
He is survived by his wife, Masako Inagami; daughters, Sanae Inagami and Mari Inagami; son-in-law, Ananth Krishnamurthy; and five grandchildren.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in People
People highlights or most popular articles

How undergrad research catalyzes scientific careers
Undergraduate research doesn’t just teach lab skills, it transforms scientists. For Antonio Rivera and Julissa Cruz–Bautista, joining a lab became a turning point, fostering critical thinking, persistence and research identity.

Simcox and Gisriel receive mentoring award
They were honored for contributing their time, knowledge, energy and enthusiasm to mentoring postdocs in their labs.

ASBMB names 2025 Marion B. Sewer scholarship recipients
Ten undergraduates interested in biochemistry and molecular biology will each receive $2,000 toward their tuition and related educational costs.

Attie named honorary professor
This award includes $100,000 of research funding and recognizes faculty who have made major contributions to the advancement of knowledge through their research, teaching and service activities.

Meet the 2025 SOC grant awardees
Five science outreach and communication projects received up to $1,000 from ASBMB to promote the understanding of molecular life science.

Unraveling cancer’s spaghetti proteins
MOSAIC scholar Katie Dunleavy investigates how Aurora kinase A shields oncogene c-MYC from degradation, using cutting-edge techniques to uncover new strategies targeting “undruggable” molecules.